REPORT on the results of clinical study of peptide bioregulator Taxorest

Written by KHAVINSON, Ph.D., Vladimir

Translated from Russian


The Director of the Medical Center

of Saint Petersburg Institute of Bioregulation and Gerontology, corresponding member of the Academy of Sciences, professor, Doctor of Medical Sciences


                                                            (signed)                       V.KH. KHAVINSON

January 25, 2006

Seal: Saint Petersburg, Limited Liability Company. Medical Center of Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences

REPORT of clinical study  of biologically active food supplement Taxorest

        Saint Petersburg


Biologically active food supplement Taxorest contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from bronchial mucosa of young animals – calves up to 12 month of age or pigs.  

            Taxorest is manufactured in the form of capsules with active substance content of 10 mg.

Experimental studies have shown that peptides have tissue-specific action on the cells of the tissues they were isolated from. Taxorest peptides regulate metabolism processes in the bronchial mucosa cells, improve their safety margin, have a favorable effect on organism adaptive capabilities in extreme conditions, possess antioxidant properties, regulate peroxidation processes in the bronchial mucosa tissues. Thus it can be expected that Taxorest is efficient for restoration of respiratory system functions at their disorders of various genesis, including decrease in bronchi spare capacity at ageing.

Chronic bronchitis is a major medical-social issue due to high dissemination, increasing morbidity, causing economic damage to the society. Chronic bronchitis is the main form of chronic non-specific lung diseases (3, 4).

            Drug treatment of the chronic bronchitis includes administration of the following medicines (1, 2):

            – antibiotics (penicillin, kanamycin, oleandomycin);

            – sulfanilamide preparations (biseptol, madribon);

            – bronchial dilatators (euphylline, ephedrine, salbutamol, phentolamine);

            – expectorants (bromhexine, thermopsis);

            – immunomodulatory drugs (tymaline, tactivine);

            – glucocorticoids (hydrocortisone, prednisolone, dexamethasone) etc.

Clinic characteristic of the patients

Clinical study of Taxorest application efficiency was conducted at the Medical center of Saint Petersburg Institute of Bioregulation and Gerontology during the period from April till November 2011.        

   The study included 52 patients at the age from 35 to 73 years, including 35 men and 17 women with chronic bronchitis in remission phase. The patients were divided into 2 groups. Patients of the basic groups were administered with Taxorest in addition to the general therapy – 1 capsule 2 times a day at mealtimes for 30 days.

The control group included 21 patients with their diagnosis, sex and age comparable to the patients of the basic group. Patients of the control group have been taking only general purpose therapy.

            Patients of both groups have been complaining of moist cough, mostly in the morning, general weakness, sweatiness, dyspnea at physical load, periodic asthma attacks, sleep disturbances, headaches. All the examined patients were smokers.

Methods of examination

            The complaints of the patients were dynamically assessed, general clinical blood analysis, urine analysis, biochemical blood analysis using “REFLOTRON” device (Boehringer Mannheim, Germany) was carried out. Lung x-ray, microscopic sputum examination and analysis of respiratory functions were also conducted.

Results of examination

            It was established that administration of Taxorest in addition to the general purpose therapy to patients with chronic bronchitis in 82% of cases resulted in health improvement, decrease in cough frequency, asthma attacks and reduction in the amount of sputum.  Positive dynamics of subjective parameters in the control group was registered in 57% of patients.

            Dynamic lung auscultation was indicative of a decrease in dry sibilant and buzzing rales.

            During the period of Taxorest administration a decrease in the number of microscopic sputum structures was observed: leucocytes, epithelial cells, Curschmann’s spirals, which is indicative of a decrease in inflammatory and bronchospastic signs of the disease.

            Examination of the respiratory function has shown that the Taxorest treatment has resulted in improvement of bronchial conductance (table 1).

Table 1

Taxorest influence on respiratory function parameters in patients with chronic bronchitis


Before treatment

After treatment

using general purpose medicines

After treatment using 


Vital capacity

(VC), ml



4220,7 ±243,1*

Total lung capacity (TLC), ml




Expiration forced vital capacity (EFVC), ml




            * р<0,05 – in comparison with the index rate before treatment.

            Results of the respiratory function examination were indicative of compensated pathological process in the lungs, but at the same time there were signs of bronchial conductance disorder, mostly due to spasm of the small bronchioles. Administration of Taxorest had positive influence on the dynamics of the process.

            Thus the results of the study performed are indicative of the treatment efficiency of Taxorest and expediency of its administration for complex treatment of chronic bronchitis, including smokers cough.

            Taxorest administration did not result in any side effects, complications and drug dependence.

            Taxorest can be used for medical and preventive purpose as a biologically active food supplement combined with any means of symptomatic and pathogenetic therapy used for chronic bronchitis treatment.


            Biologically active food supplement Taxorest normalizes functional activity of the bronchial mucosa cells.

            Taxorest is well tolerated at oral administration, has no side effects and can be used as treatment-prophylactic biologically active food additive.

            Taxorest is recommended for patients with respiratory dysfunction, including chronic bronchitis of various origins, per os at mealtime 1-2 capsules 2 times a day for 30 days.

            A repeated course in 3-6 months is advisable.



  1. Belousov Y.B., Moiseev V.S., Lepakhin V.K. Clinical pharmacology and pharmacotherapy: Manual for doctors. – М.: Universum, 1993. – 398 pages.
  2. Mashkovsky M.D. Medicines: Pharmacotherapy manual for healthcare professionals: 2 parts – Vilnus: ZAO “Gamta”, 1993.
  3. Paleev N.R., Tsarkova L.N., Borokhov A.I. Chronic non-specific pulmonary diseases. – М.: Medicine, 1985. – 240 pages.
  4. Tsarkova L.N., Ilchenko V.A. Chronic non-specific pulmonary diseases/ Diagnostics and treatment of internal diseases: Manual for doctors. Edited by F.I. Komarov. – М.: Medicine, 1991. – Vol. 2. – Pages 106-250.

Recommendations for use

     Taxorest is a complex of peptides, received from bronchial mucosa of young animals.  The isolated peptides have selective effect on the bronchial mucosa cells, normalize their metabolism and regulate respiratory system functions. 

The clinical study has helped to establish the efficiency of Taxorest for complex treatment of patients with chronic bronchitis of various origins, restoration of the respiratory system functions after diseases of various origins or after exposure to extreme environmental factors, hypoalimentation, and at ageing.

Taxorest should be taken per os at mealtime 1-2 capsules 1-2 times a day.  The period of administration makes 30 days.  It is reasonable to have a repeated course in 4-6 month.

         Contraindications: individual intolerance to the components, pregnancy, breast feeding.

Administration of Taxorest has not resulted in any side effects.

It is recommended to store in a dry dark place at the temperature from +2 up to +25ºС.

Pharmaceutical form: 20 capsules or tablets of Taxorest 10 mg each.

Period of validity – 3 years from the day of manufacturing.


Executive officer:

Deputy Director of LLC “Medical Center of Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences” in charge of clinical affairs, Ph.D., assistant professor





________________________A.A. Veretenko

Action officer:

Chief Physician of LLC “Medical Center of Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences”, Ph.D.





_____________________O.Y. Raygorodsky